Investors in Alto Neuroscience should take note of a recently filed class action lawsuit concerning the company’s IPO and subsequent securities. This development underscores the potential legal and financial implications for shareholders who participated in the initial public offering or traded during the specified period.
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024. Alto describes itself as a “clinical-stage biopharmaceutical company in the U.S.” For more infor
Source: Original Press Release